Merck announces FDA acceptance of biologics license application for Clesrovimab
An investigational long-acting monoclonal antibody designed to protect infants from RSV disease during their first RSV season
An investigational long-acting monoclonal antibody designed to protect infants from RSV disease during their first RSV season
Harnessing advanced data analysis for early detection, prevention and better outcomes
Dr. Berger is a board-certified internist, hematologist and oncologist who brings more than 25 years of extensive experience in developing and delivering innovative medicines
IBRANCE is the first CDK4/6 inhibitor to show benefit in a large Phase 3 trial in first-line HR+, HER2+ metastatic breast cancer, in combination with anti-HER2 and endocrine therapy
First and only PARP inhibitor to improve overall survival in early breast cancer
Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease
Vepdegestrant in combination with abemaciclib demonstrated encouraging clinical activity (clinical benefit rate
Showing High Overall Response Rate (ORR) with durable responses and favorable safety profile in patients with heavily pretreated multiple myeloma
Partnership to supercharge LVMH Recherche with Integrated Biosciences’ innovative AI and synthetic biology platform for targeting skin aging
Subscribe To Our Newsletter & Stay Updated